S
Siddhartha Mukherjee
Researcher at Harvard University
Publications - 26
Citations - 1526
Siddhartha Mukherjee is an academic researcher from Harvard University. The author has contributed to research in topics: Bone marrow & Leukemia. The author has an hindex of 13, co-authored 26 publications receiving 1379 citations. Previous affiliations of Siddhartha Mukherjee include University of Florida & National Institute of Technology, Tiruchirappalli.
Papers
More filters
Journal ArticleDOI
Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage
Seth D. Berman,Eliezer Calo,Allison S. Landman,Paul S. Danielian,Emily S. Miller,Julie C. West,Borel Djouedjong Fonhoue,Alicia M. Caron,Roderick T. Bronson,Mary L. Bouxsein,Siddhartha Mukherjee,Jacqueline A. Lees +11 more
TL;DR: It is shown that loss of Rb and p53 in Sca-1-positive mesenchymal stem/progenitor cells is sufficient to yield transformed cells that can initiate osteosarcoma formation in vivo.
Journal ArticleDOI
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet,Siddhartha Mukherjee,Siddhartha Mukherjee,Nileshwari Vaghela,Teru Hideshima,Mariateresa Fulciniti,Mariateresa Fulciniti,Samantha Pozzi,Loredana Santo,Diana Cirstea,Kishan Patel,Aliyah R. Sohani,A.R. Guimaraes,Wanling Xie,Dharminder Chauhan,Jesse Schoonmaker,Eyal C. Attar,Michael Churchill,Edie Weller,Nikhil C. Munshi,Nikhil C. Munshi,Jasbir Seehra,Ralph Weissleder,Kenneth C. Anderson,David T. Scadden,Noopur Raje +25 more
TL;DR: Targeting activin A by a soluble decoy receptor reversed osteoblast inhibition, ameliorated MM bone disease, and inhibited tumor growth in an in vivo humanized MM model, setting the stage for testing in human clinical trials.
Journal ArticleDOI
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
Diana Cirstea,Teru Hideshima,Scott J. Rodig,Loredana Santo,Samantha Pozzi,Sonia Vallet,Hiroshi Ikeda,Giulia Perrone,Gullu Gorgun,Kishan Patel,Neil P. Desai,Peter Sportelli,Shweta Kapoor,Shireen Vali,Siddhartha Mukherjee,Nikhil C. Munshi,Kenneth C. Anderson,Noopur Raje +17 more
TL;DR: It is suggested that mutual suppression of the PI3K/Akt/mTOR pathway by rapamycin and perifosine combination induces synergistic MM cell cytotoxicity, providing the rationale for clinical trials in patients with relapsed/refractory MM.
Journal ArticleDOI
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
Sonia Vallet,Noopur Raje,Kenji Ishitsuka,Teru Hideshima,Klaus Podar,Shweta Chhetri,Samantha Pozzi,Iris Breitkreutz,Tanyel Kiziltepe,Hiroshi Yasui,Enrique M. Ocio,Norihiko Shiraishi,Janice Jin,Yutaka Okawa,Hiroshi Ikeda,Siddhartha Mukherjee,Nileshwari Vaghela,Diana Cirstea,Marco Ladetto,Mario Boccadoro,Kenneth C. Anderson +20 more
TL;DR: Novel biologic sequelae of CCL3 and its inhibition in both osteoclastogenesis and MM cell growth are shown, providing the preclinical rationale for clinical trials of MLN3897 to treat OBD in MM.
Journal ArticleDOI
Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts
Maria Krevvata,Barbara C. Silva,John S. Manavalan,Marta Galán-Díez,Aruna Kode,Brya G. Matthews,David C. Park,Chiyuan A. Zhang,Naomi Galili,Thomas L. Nickolas,David W. Dempster,William C. Dougall,Julie Teruya-Feldstein,Aris N. Economides,Ivo Kalajzic,Azra Raza,Ellin Berman,Siddhartha Mukherjee,Govind Bhagat,Stavroula Kousteni +19 more
TL;DR: The results suggest that osteoblasts play a fundamental role in propagating leukemia in the marrow and may be a therapeutic target to induce hostility of the niche to leukemia blasts.